Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany.
Department of Dermatology, Johannes Wesling Klinikum Minden, Minden, Germany.
J Dtsch Dermatol Ges. 2020 Mar;18(3):193-197. doi: 10.1111/ddg.14044. Epub 2020 Feb 20.
Radiotherapy, particularly total skin electron beam therapy (TSEB), is one of the main pillars in the strategy for treatment of cutaneous T-cell lymphoma (CTCL). Low-dose TSEB has gained considerable attention since it has a minimal toxicity profile. Low-dose TSEB has been shown to yield an overall response rate up to 95 %, although the response duration is usually short. Few studies have been published on treatment outcomes after combined treatment of CTCL with TSEB and systemic therapy. Remission rates of patients who received immune checkpoint inhibitors alone ranged from 15-38 % with a two-year progression-free survival of 69 %. Given that TSEB results in rapid reduction of the disease burden in almost all patients, we hypothesized that TSEB followed by immune checkpoint inhibitors might be a reasonable treatment with a sustained effect for treatment-experienced patients with mycosis fungoides and Sezary syndrome.
放射治疗，特别是全身电子束疗法（TSEB），是治疗皮肤 T 细胞淋巴瘤（CTCL）策略的主要支柱之一。低剂量 TSEB 因其具有最小的毒性特征而受到广泛关注。低剂量 TSEB 的总体缓解率高达 95%，尽管缓解持续时间通常较短。关于 CTCL 采用 TSEB 联合全身治疗后的治疗结果的研究很少。单独接受免疫检查点抑制剂治疗的患者的缓解率为 15-38%，两年无进展生存率为 69%。鉴于 TSEB 几乎使所有患者的疾病负担迅速减轻，我们假设 TSEB 后再使用免疫检查点抑制剂可能是一种合理的治疗方法，对有治疗经验的蕈样真菌病和 Sezary 综合征患者具有持续疗效。
